MedPath

MEDA PHARMACEUTICALS INC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

20

Active:1
Completed:19

Trial Phases

3 Phases

Phase 1:1
Phase 3:18
Phase 4:1

Drug Approvals

2

FDA:2

Drug Approvals

Gastrocrom

Approval Date
Oct 10, 2018
FDA

URELLE

Approval Date
Jan 13, 2015
FDA

Clinical Trials

Distribution across different clinical trial phases (20 trials with phase data)• Click on a phase to view related trials

Phase 3
18 (90.0%)
Phase 1
1 (5.0%)
Phase 4
1 (5.0%)

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

Phase 3
Completed
Conditions
Seasonal Allergic Rhinitis
Interventions
First Posted Date
2013-08-05
Last Posted Date
2015-06-29
Lead Sponsor
Meda Pharmaceuticals
Target Recruit Count
348
Registration Number
NCT01915823
Locations
🇺🇸

Clinical Research Center of Alabama,LLC, Birmingham, Alabama, United States

🇺🇸

Little Rock Allergy and Asthma Clinical research Center, Little Rock, Alaska, United States

🇺🇸

Clinical Research Atlanta, Atlanta, Georgia, United States

and more 28 locations

Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR

Phase 4
Completed
Conditions
Allergic Rhinitis
Interventions
Drug: 205.5 mcg of azelastine hydrochloride
Drug: 137 mcg of azelastine hydrochloride
First Posted Date
2013-06-19
Last Posted Date
2015-06-29
Lead Sponsor
Meda Pharmaceuticals
Target Recruit Count
191
Registration Number
NCT01880840
Locations
🇺🇸

Clinical Research Center of Alabama,LLC, Birmingham, Alabama, United States

🇺🇸

Little Rock Allergy and Asthma Clinical research Center, Little Rock, Alaska, United States

🇺🇸

West Coast Clinical Trials, Costa Mesa, California, United States

and more 11 locations

3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis

Phase 3
Completed
Conditions
Allergic Rhinitis
Interventions
First Posted Date
2013-02-20
Last Posted Date
2015-03-31
Lead Sponsor
Meda Pharmaceuticals
Target Recruit Count
405
Registration Number
NCT01794741
Locations
🇺🇸

Clinical Research Center of Alabama,LLC, Birmingham, Alabama, United States

🇺🇸

Little Rock Allergy and Asthma Clinical research Center, Little Rock, Alaska, United States

🇺🇸

West Coast Clinical Trials, Costa Mesa, California, United States

and more 38 locations

Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old

Phase 3
Completed
Conditions
Herpes Labialis
Interventions
Drug: acyclovir/hydrocortisone cream
First Posted Date
2012-04-10
Last Posted Date
2014-05-22
Lead Sponsor
Meda Pharmaceuticals
Target Recruit Count
54
Registration Number
NCT01574612
Locations
🇺🇸

MCS Clinical Trials, Los Angeles, California, United States

🇺🇸

Sunshine Research Center, Opa-Locka, Florida, United States

🇺🇸

Altus Rsearch,INC, West Palm Beach, Florida, United States

and more 7 locations

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies

First Posted Date
2011-06-08
Last Posted Date
2011-10-06
Lead Sponsor
Meda Pharmaceuticals
Target Recruit Count
617
Registration Number
NCT01368445
Locations
🇺🇸

AABI Associates Medical Group, Fountain Valley, California, United States

🇺🇸

West Coast Clinical Trials, Long Beach, California, United States

🇺🇸

Allergy Research Foundation, Los Angeles, California, United States

and more 27 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.